Research programme: cyclodextrin-based therapeutics - BioAxis Research/Okklo Life Sciences
Latest Information Update: 17 Aug 2016
At a glance
- Originator BioAxis Research; Okklo Life Sciences
- Class Cyclodextrins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 17 Aug 2016 Preclinical trials in Undefined indication in Netherlands (unspecified route)